Indivior Reports Studies Showing Sublocade Reduces Opioid Relapse Risk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Indivior Pharmaceuticals announced results from two real-world evidence studies showing that adherence to extended-release buprenorphine, marketed as Sublocade, is associated with lower relapse risk and reduced healthcare utilization among patients with opioid use disorder. One analysis of 3,400 patients found those adherent to the treatment were 3.5 to 8.1 times less likely to return to opioid use compared to non-adherent patients. A second study demonstrated a 62% reduction in bacteremia incidence compared to patients receiving daily oral buprenorphine, as well as significantly fewer inpatient and emergency department visits.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.130
Low
36.00
Averages
43.75
High
50.00
Current: 38.130
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Indivior Executive Sells Shares Amid Strong Market Performance
- Executive Stock Sale: On June 11, 2026, Indivior's Chief Scientific Officer Christian Heidbreder sold 18,586 shares of common stock for $707,383, reflecting a 7.54% reduction in his direct holdings at that time.
- Post-Transaction Holdings: Following the sale, Heidbreder retains 227,923 shares valued at approximately $8.69 million, maintaining a 0.18% ownership stake in the company, which indicates his continued confidence in Indivior's prospects.
- Financial Performance: Indivior reported a first-quarter revenue of $317 million in 2026, up from $266 million in 2025, with net income increasing from $47 million to $89 million, showcasing effective cost management as operating expenses were reduced from $156 million to $139 million.
- Market Reaction and Strategy: The stock sale occurred as Indivior's share price rebounded from a 52-week low of $13.45 to $41, and was executed under a pre-arranged trading plan, suggesting that the transaction is not a red flag for investors and reinforcing market confidence.
See More
Indivior's Chief Scientific Officer Sells Shares Amid Stock Surge
- Share Sale Details: On June 11, 2026, Christian Heidbreder, Chief Scientific Officer of Indivior, sold 18,586 shares for approximately $707,000, representing 7.54% of his direct holdings, reducing his position from 246,509 to 227,923 shares, indicating executive responsiveness to market conditions.
- Transaction Context: This sale occurred as the stock rebounded from a 52-week low of $13.45 to a high of $41 in May, and despite the soaring price, Heidbreder's sale is not seen as a red flag for investors since it was a non-discretionary disposition under a pre-arranged Rule 10b5-1 trading plan established in March 2026.
- Company Financial Performance: Indivior reported a first-quarter sales increase to $317 million from $266 million in 2025, with net income rising significantly from $47 million to $89 million, showcasing the company's effective cost management alongside revenue growth.
- Market Outlook Consideration: While Indivior's financial results are strong, analysts have noted that the company was not included in the latest list of top investment stocks, suggesting that investors should exercise caution when considering investments in a competitive pharmaceutical landscape.
See More
Indivior Pharmaceuticals Stock Investment Outlook
- Significant Performance Growth: Indivior raised its full-year net revenue guidance to $1.215–$1.285 billion on April 30, 2026, with Q1 revenue reaching $317 million, a 19% year-over-year increase, highlighting the strong growth potential of its SUBLOCADE product line.
- Shareholder Return Strategy: The company announced a $175 million accelerated share repurchase plan scheduled for completion by the end of June 2026, following $125 million in buybacks in Q1, indicating a commitment to enhancing shareholder value and implying a reduction of over 6% in the share count.
- Market Confidence Restoration: Despite skepticism surrounding pipeline project failures, improvements in Indivior's profitability and cash flow could lead to a re-rating of its stock, with future EBITDA multiples potentially reaching 9-10x, offering significant upside potential.
- Investor Attention Shift: As of the first quarter, 42 hedge funds held INDV, down from 45 in the previous quarter, indicating a decrease in interest; however, the market still recognizes Indivior's potential value within investment portfolios despite associated risks.
See More
Analysis of High-Efficiency Stock Screening
- Efficiency Metrics: By screening efficiency ratios, companies like Indivior Pharmaceuticals, ReNew Energy Global, Lifetime Brands, NetScout Systems, and Teekay Tank emerged from a pool of 7,906 stocks, indicating strong profit-generating potential.
- Earnings Surprise: Indivior Pharmaceuticals boasts a 65.4% average earnings surprise over four quarters, highlighting its success in drug development, which may attract more investor interest in its future growth prospects.
- Renewable Energy Edge: ReNew Energy Global's average earnings surprise of 57.9% over four quarters reflects its robust performance in renewable energy projects, aligning with the global shift towards green energy and enhancing its market competitiveness.
- Diverse Product Line: Lifetime Brands has a 50% average earnings surprise over four quarters, and its diversified product line in kitchenware and home accessories helps increase market share, further solidifying its industry leadership.
See More
Divisadero Street Capital Reduces Indivior Stake
- Share Reduction Transaction: Divisadero Street Capital Management disclosed a sale of 2,263,703 shares of Indivior in Q1 2026, valued at approximately $74.76 million, indicating ongoing confidence in Indivior despite a $84.04 million decrease in stake value due to price fluctuations.
- Holding Proportion Change: Post-sale, Indivior now represents only 0.7% of Divisadero's reportable assets, reflecting a relative decline in its significance within the portfolio, yet it remains a key profit contributor.
- Strong Performance Growth: Indivior reported a 19% year-over-year revenue increase to $317 million in Q1, driven largely by a 32% surge in SUBLOCADE sales, indicating sustained demand and market share growth in the opioid dependence treatment sector.
- Optimistic Future Outlook: Indivior's management raised its 2026 revenue guidance to $1.29 billion and adjusted EBITDA expectations to $660 million, showcasing the company's potential for growth as SUBLOCADE adoption accelerates, positioning it for the next phase of expansion.
See More
Divisadero Street Capital Reduces Indivior Stake
- Share Reduction Transaction: Divisadero Street Capital Management sold 2,263,703 shares of Indivior in the first quarter, with an estimated trade value of $74.76 million, reflecting its strategic response to market fluctuations.
- Decline in Position Value: The fund's Indivior stake saw a decrease of $84.04 million by quarter-end, indicating the dual impact of the share sale and price movements, suggesting a potential waning interest in the stock.
- Sustained Performance Growth: Indivior reported a 19% year-over-year revenue increase in Q1, reaching $317 million, primarily driven by a 32% surge in SUBLOCADE sales, highlighting strong demand in the pharmaceutical treatment sector.
- Optimistic Future Outlook: Indivior's management raised its 2026 revenue guidance to a potential $1.29 billion, reflecting confidence in future growth, particularly with the ongoing adoption of SUBLOCADE and increasing cash generation capabilities.
See More
Indivior Executive Sells Shares Amid Strong Market Performance
- Executive Stock Sale: On June 11, 2026, Indivior's Chief Scientific Officer Christian Heidbreder sold 18,586 shares of common stock for $707,383, reflecting a 7.54% reduction in his direct holdings at that time.
- Post-Transaction Holdings: Following the sale, Heidbreder retains 227,923 shares valued at approximately $8.69 million, maintaining a 0.18% ownership stake in the company, which indicates his continued confidence in Indivior's prospects.
- Financial Performance: Indivior reported a first-quarter revenue of $317 million in 2026, up from $266 million in 2025, with net income increasing from $47 million to $89 million, showcasing effective cost management as operating expenses were reduced from $156 million to $139 million.
- Market Reaction and Strategy: The stock sale occurred as Indivior's share price rebounded from a 52-week low of $13.45 to $41, and was executed under a pre-arranged trading plan, suggesting that the transaction is not a red flag for investors and reinforcing market confidence.
See More
Indivior's Chief Scientific Officer Sells Shares Amid Stock Surge
- Share Sale Details: On June 11, 2026, Christian Heidbreder, Chief Scientific Officer of Indivior, sold 18,586 shares for approximately $707,000, representing 7.54% of his direct holdings, reducing his position from 246,509 to 227,923 shares, indicating executive responsiveness to market conditions.
- Transaction Context: This sale occurred as the stock rebounded from a 52-week low of $13.45 to a high of $41 in May, and despite the soaring price, Heidbreder's sale is not seen as a red flag for investors since it was a non-discretionary disposition under a pre-arranged Rule 10b5-1 trading plan established in March 2026.
- Company Financial Performance: Indivior reported a first-quarter sales increase to $317 million from $266 million in 2025, with net income rising significantly from $47 million to $89 million, showcasing the company's effective cost management alongside revenue growth.
- Market Outlook Consideration: While Indivior's financial results are strong, analysts have noted that the company was not included in the latest list of top investment stocks, suggesting that investors should exercise caution when considering investments in a competitive pharmaceutical landscape.
See More
Indivior Pharmaceuticals Stock Investment Outlook
- Significant Performance Growth: Indivior raised its full-year net revenue guidance to $1.215–$1.285 billion on April 30, 2026, with Q1 revenue reaching $317 million, a 19% year-over-year increase, highlighting the strong growth potential of its SUBLOCADE product line.
- Shareholder Return Strategy: The company announced a $175 million accelerated share repurchase plan scheduled for completion by the end of June 2026, following $125 million in buybacks in Q1, indicating a commitment to enhancing shareholder value and implying a reduction of over 6% in the share count.
- Market Confidence Restoration: Despite skepticism surrounding pipeline project failures, improvements in Indivior's profitability and cash flow could lead to a re-rating of its stock, with future EBITDA multiples potentially reaching 9-10x, offering significant upside potential.
- Investor Attention Shift: As of the first quarter, 42 hedge funds held INDV, down from 45 in the previous quarter, indicating a decrease in interest; however, the market still recognizes Indivior's potential value within investment portfolios despite associated risks.
See More
Analysis of High-Efficiency Stock Screening
- Efficiency Metrics: By screening efficiency ratios, companies like Indivior Pharmaceuticals, ReNew Energy Global, Lifetime Brands, NetScout Systems, and Teekay Tank emerged from a pool of 7,906 stocks, indicating strong profit-generating potential.
- Earnings Surprise: Indivior Pharmaceuticals boasts a 65.4% average earnings surprise over four quarters, highlighting its success in drug development, which may attract more investor interest in its future growth prospects.
- Renewable Energy Edge: ReNew Energy Global's average earnings surprise of 57.9% over four quarters reflects its robust performance in renewable energy projects, aligning with the global shift towards green energy and enhancing its market competitiveness.
- Diverse Product Line: Lifetime Brands has a 50% average earnings surprise over four quarters, and its diversified product line in kitchenware and home accessories helps increase market share, further solidifying its industry leadership.
See More
Divisadero Street Capital Reduces Indivior Stake
- Share Reduction Transaction: Divisadero Street Capital Management disclosed a sale of 2,263,703 shares of Indivior in Q1 2026, valued at approximately $74.76 million, indicating ongoing confidence in Indivior despite a $84.04 million decrease in stake value due to price fluctuations.
- Holding Proportion Change: Post-sale, Indivior now represents only 0.7% of Divisadero's reportable assets, reflecting a relative decline in its significance within the portfolio, yet it remains a key profit contributor.
- Strong Performance Growth: Indivior reported a 19% year-over-year revenue increase to $317 million in Q1, driven largely by a 32% surge in SUBLOCADE sales, indicating sustained demand and market share growth in the opioid dependence treatment sector.
- Optimistic Future Outlook: Indivior's management raised its 2026 revenue guidance to $1.29 billion and adjusted EBITDA expectations to $660 million, showcasing the company's potential for growth as SUBLOCADE adoption accelerates, positioning it for the next phase of expansion.
See More
Divisadero Street Capital Reduces Indivior Stake
- Share Reduction Transaction: Divisadero Street Capital Management sold 2,263,703 shares of Indivior in the first quarter, with an estimated trade value of $74.76 million, reflecting its strategic response to market fluctuations.
- Decline in Position Value: The fund's Indivior stake saw a decrease of $84.04 million by quarter-end, indicating the dual impact of the share sale and price movements, suggesting a potential waning interest in the stock.
- Sustained Performance Growth: Indivior reported a 19% year-over-year revenue increase in Q1, reaching $317 million, primarily driven by a 32% surge in SUBLOCADE sales, highlighting strong demand in the pharmaceutical treatment sector.
- Optimistic Future Outlook: Indivior's management raised its 2026 revenue guidance to a potential $1.29 billion, reflecting confidence in future growth, particularly with the ongoing adoption of SUBLOCADE and increasing cash generation capabilities.
See More
